Search

Pegvaliase is approved to reduce phenylalanine (Phe) levels for people with phenylketonuria (PKU). PRISM‐1 (NCT01819727) and PRISM‐2 (NCT01889862) data were analyzed to evaluate the relationship between Phe and inattention in adult participants with PKU. In the modified‐intent‐to‐treat population (N = 156), baseline mean (SE) plasma Phe was 1263 (29) μmol/L and the Attention Deficit Hyperactivity Disorder Rating Scale‐IV Inattentive (IA) symptoms score was 9.8 (0.5). Mean (SE) IA scores fell 9.0 (1.1) in Quartile 1 (Phe reduction between 1166 and 2229 μmol/L) versus 4.3 (0.7) in Quartile 4 (Phe reduction of 139 μmol/L to increase of 934 μmol/L), p = 0.004. Least squares mean (SE) change from baseline IA score was −7.9 (0.7) for participants with final Phe ≤ 360 μmol/L and −4.5 (0.7) for final Phe > 360 μmol/L, p < 0.001. In the inattention subgroup, IA scores fell 13.3 (1.5) in Quartile 1 (Phe reduction between 1288 and 2229 μmol/L) versus 6.2 (1.3) in Quartile 4 (Phe reduction of 247 to increase of 934 μmol/L), p = 0.009. Inattention symptoms improved among those whose Phe levels decreased, particularly those with high baseline IA scores. IA improvements were larger among participants with the greatest plasma Phe reductions, supporting this value as a therapeutic goal. [ABSTRACT FROM AUTHOR]

The article focuses on the study that assessed the relationship between baseline body mass index (BMI) and change in body weight (BW) during the 6-month study on obese patients. It states that insulin detemir was given as an add-on therapy to any other glucose-lowering regimens, or as a replacement of previous basal insulin in subjects with type 2 diabetes. It notes that use of detemir as basal insulin has led to the improvement in A1C levels, irrespective of patient weight.

The article focuses on the findings of PREDICTIVE, a multinational, observational study that aims to determine the safety and efficiency of insulin detemir on patients from 6 European countries. It notes that transferring to detemir significantly improved glycemic control and significantly reduced incidence of hypoglycemia. It mentions that 5.2 percent of patients reported serious adverse drug reactions including major hypoglycemic events.